HDM1005 vs NNC0519-0130
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/GIP receptor (dual) · full Obesity pipeline
HDM1005
Developed by Hangzhou Zhongmei Huadong Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT07502001 (registry estimate)
No aligned efficacy figure on record for this race.
NNC0519-0130
Developed by Novo Nordisk
NCT06326060 · Phase 2 · completed
The study was randomized and quadruple-blind, included placebo and active-comparator arms, and enrolled 354 participants; its primary endpoint was the clinical measure of relative body-weight change. Because the registry does not report whether this endpoint was met, the findings cannot currently support the highest evidence grade.
No aligned efficacy figure on record for this race.
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | HDM1005 | NNC0519-0130 |
|---|---|---|
| Body weight, % change | —Trial running · NCT07279194 | —Not reported |
| Weight loss of 5% or more | —Trial running · NCT07279194 | —Not reported |
| Weight loss of 10% or more | —Trial running · NCT07279194 | —Not reported |
| Waist circumference, change (cm) | —Trial running · NCT07279194 | —Not reported |
Body weight, % change
- HDM1005
- —Trial running · NCT07279194
- NNC0519-0130
- —Not reported
Weight loss of 5% or more
- HDM1005
- —Trial running · NCT07279194
- NNC0519-0130
- —Not reported
Weight loss of 10% or more
- HDM1005
- —Trial running · NCT07279194
- NNC0519-0130
- —Not reported
Waist circumference, change (cm)
- HDM1005
- —Trial running · NCT07279194
- NNC0519-0130
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
HDM1005: no structured comparison results are available for Obesity.
NNC0519-0130: no structured comparison results are available for Obesity.
Type 2 Diabetes
Shared mechanism: GLP-1/GIP receptor (dual) · full Type 2 Diabetes pipeline
HDM1005
Developed by Hangzhou Zhongmei Huadong Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: August 2027 · NCT07394114 (registry estimate)
No aligned efficacy figure on record for this race.
NNC0519-0130
Developed by Novo Nordisk
NCT05363774 · Phase 1 · completed
This was a randomized, blinded, placebo-controlled study, a genuine controlled design, but it measured only safety and drug levels rather than a clinical efficacy outcome, and results have not been posted yet, so the evidence reflects the design only. Its registered primary outcome on ClinicalTrials.gov is "Number of treatment emergent adverse events (TEAE) in single ascending dose (SAD) part" (with 3 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | HDM1005 | NNC0519-0130 |
|---|---|---|
| HbA1c, change | —Trial running · NCT07394114 | —Not reported |
| Body weight, change (kg) | —Trial running · NCT07394114 | —Not reported |
| HbA1c below 7% | —Trial running · NCT07394114 | —Not reported |
| Fasting plasma glucose, change | —Trial running · NCT07394114 | —Not reported |
| 3-point MACE (% with event) | —Trial running · NCT07394114 | —Not reported |
HbA1c, change
- HDM1005
- —Trial running · NCT07394114
- NNC0519-0130
- —Not reported
Body weight, change (kg)
- HDM1005
- —Trial running · NCT07394114
- NNC0519-0130
- —Not reported
HbA1c below 7%
- HDM1005
- —Trial running · NCT07394114
- NNC0519-0130
- —Not reported
Fasting plasma glucose, change
- HDM1005
- —Trial running · NCT07394114
- NNC0519-0130
- —Not reported
3-point MACE (% with event)
- HDM1005
- —Trial running · NCT07394114
- NNC0519-0130
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
HDM1005: no structured comparison results are available for Type 2 Diabetes.
NNC0519-0130: no structured comparison results are available for Type 2 Diabetes.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HDM1005's landscape · NNC0519-0130's landscape